Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial

Annals of the Rheumatic Diseases

Volumn 75, Issue 12, 2016, Pages 2119-2123

  Kuijper, T M ^a,b   Luime, J J ^b   De Jong, P H P ^a   Gerards, A H ^c   Van Zeben, D ^d   Tchetverikov, I ^e   De Sonnaville, P B J ^f,g   Van Krugten, M V ^f,h   Grillet, B A ^i,j,k   Hazes, J M W ^b   Weel, A E A M ^a,b  

^a Maasstad Hospital   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Department of Orthopaedic Surgery and Traumatology Vlietland Hospital   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^f Admiraal de Ruyter Hospital   (Netherlands)

^g Reumazorg Zuid West Nederland   (Netherlands)

^h Reumazorg Zuid West Nederland   (Netherlands)

ⁱ Admiraal de Ruyter Hospital   (Netherlands)

^j ZorgSaam Hospital   (Netherlands)

^k Reumazorg Zuid West Nederland   (Netherlands)

more..

Author keywords

Disease Activity; DMARDs (biologic); DMARDs (synthetic); Early Rheumatoid Arthritis; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TIME FACTOR;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; SYMPTOM FLARE UP; TIME FACTORS;

EID: 84973514570     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209272     Document Type: Article

References (17)

1. de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73:1331-9.
2. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
3. ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 2015;74:1233-40.
4. Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, et al. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 2015;42:2012-22.
5. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
6. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
7. Aletaha D, Neogi T, Silman AJ III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
8. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
9. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006;24(Suppl 43):S-77-82.
10. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59-67.
11. Moghadam MG, Vonkeman HE, Ten Klooster PM, et al. Stopping tumor necrosis factor-inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open-label controlled trial. Arthritis Rheumatol 2016. Published Online First 11 Feb 2016.
12. van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75:52-8.
13. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016;75:45-51.
14. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-19.
15. Manders SH, van de Laar MA, Rongen-van Dartel SA, et al. Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD Open 2015;1:e000147.
16. Emery P, Hammoudeh M, Fitz Gerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781-92.
17. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.